Vol - 25, Issue - 8
About the Journal
[This article belongs to Volume - 25, Issue - 8]
International Medical Journal
Journal ID : IMJ-20-07-2020-542
Total View : 334
Title : Rifaximin in hepatic encephalopathy: A review of the literature

Abstract : Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis with a great socioeconomic impact, which impairs the quality of life of patients. Non-absorbable disaccharides and rifaximin are the most commonly used treatments along with the correction of precipitating factors. There are few randomized-controlled trials and many of the current treatment recommendations are based on clinical practice. Rifaximin should start during an episode of HE if there is no clinical improvement after 24-48 hours of non-absorbable disaccharides therapy. Rifaximin as an add-on therapy to lactulose is prudent in recurrent HE in patients who develop a new episode. Rifaximin has proven an effective treatment option for overt HE and in the prevention of recurrence
Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates

Guidelines

Further Information
Copyright © 2019: International Medical Journal
//